Related Experiment Video
Updated: Jul 10, 2026
06:39
Curcuminoid-Mediated Antimicrobial Photodynamic Therapy on a Murine Model of Oral Candidiasis
Published on: October 27, 2023
Therapeutic alternatives in Behçet's syndrome
L Cobellis1, E Pecori, F Rigatti
1Department of Gynaecology, Obstetrics and Reproductive Medicine, Second University of Naples, Naples, Italy.
Clinical and Experimental Obstetrics & Gynecology
|October 17, 2007
Summary
Interferon alpha-2a, combined with other treatments, shows promise in managing Behçet
Area of Science:
- Rheumatology
- Immunology
- Dermatology
Background:
- Behçet's Syndrome (BD) is a chronic, systemic vasculitis with unknown etiology.
- Clinical manifestations stem from small-vessel vasculitis affecting multiple organs.
- Current therapies lack uniformity due to the unknown cause of BD.
Purpose of the Study:
- To evaluate therapeutic alternatives for Behçet's Syndrome.
- To investigate the efficacy of systemic interferon alpha-2a in BD treatment.
Main Methods:
- Ten patients diagnosed with Behçet's Disease were treated with prednisone, sulfasalazine, clobetasol, and interferon alpha-2a.
- Treatment protocol included monthly complete blood counts, platelet counts, and liver function tests.
- Biopsies of genital ulcerations and HLA typing were performed.
Main Results:
- Biopsies confirmed small vessel vasculitis with mononuclear cell and lymphocytic infiltrates.
- Pathergy test was positive in all patients; HLA-B27 and B5 were positive in three.
- No patients exhibited clinical symptoms of BD or intolerance during ongoing therapy; laboratory findings remained normal.
Conclusions:
- Systemic interferon alpha-2a, as part of a multi-drug regimen, appears effective in managing Behçet's Syndrome.
- The observed efficacy may be influenced by patient selection or disease severity.
- Further confirmation in larger patient cohorts is warranted.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...